Zacks: Analysts Expect CELLECT BIOTECH/S (APOP) Will Announce Earnings of -$0.28 Per Share

Wall Street analysts expect that CELLECT BIOTECH/S (NASDAQ:APOP) will post earnings per share of ($0.28) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for CELLECT BIOTECH/S’s earnings. CELLECT BIOTECH/S posted earnings of ($0.39) per share in the same quarter last year, which suggests a positive year over year growth rate of 28.2%. The company is scheduled to issue its next earnings report on Wednesday, November 28th.

According to Zacks, analysts expect that CELLECT BIOTECH/S will report full year earnings of ($0.98) per share for the current financial year. For the next financial year, analysts anticipate that the company will post earnings of ($1.33) per share. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover CELLECT BIOTECH/S.

CELLECT BIOTECH/S (NASDAQ:APOP) last posted its quarterly earnings results on Thursday, August 9th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.03.

Several brokerages have weighed in on APOP. HC Wainwright set a $14.00 price objective on shares of CELLECT BIOTECH/S and gave the stock a “buy” rating in a research note on Friday, July 6th. Zacks Investment Research cut shares of CELLECT BIOTECH/S from a “buy” rating to a “hold” rating in a research note on Tuesday, July 31st.

NASDAQ:APOP opened at $5.10 on Friday. CELLECT BIOTECH/S has a 12-month low of $4.40 and a 12-month high of $13.50. The stock has a market capitalization of $27.58 million, a P/E ratio of -3.49 and a beta of 3.70.

CELLECT BIOTECH/S Company Profile

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.

Recommended Story: How are the companies in the S&P 500 selected?

Get a free copy of the Zacks research report on CELLECT BIOTECH/S (APOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CELLECT BIOTECH/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELLECT BIOTECH/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply